Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer’s Disease Treatments Including Phase 3 Aducanumab
Go back to Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer’s Disease Treatments Including Phase 3 Aducanumab| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 198.91 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $198.91 | 52 Week High | $333.65 | |||
| Open | $198.91 | 52 Week Low | $223.02 | |||
| Day High | $198.91 | P/E | 25.47 | |||
| Day Low | $198.91 | EPS | $7.81 | |||
| Volume | 78 | |||||
